Advancements in proteogenomics for preclinical targeted cancer therapy research

被引:0
|
作者
Yuying Suo [1 ,2 ]
Yuanli Song [1 ]
Yuqiu Wang [1 ,3 ]
Qian Liu [1 ]
Henry Rodriguez [4 ]
Hu Zhou [1 ]
机构
[1] Department of Analytical Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
[2] University of Chinese Academy of Sciences
[3] Department of Otolaryngology, Eye & ENT Hospital, Fudan University
[4] Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of
关键词
D O I
暂无
中图分类号
R73-36 [治疗实验];
学科分类号
摘要
Advancements in molecular characterization technologies have accelerated targeted cancer therapy research at unprecedented resolution and dimensionality. Integrating comprehensive multi-omic molecular profiling of a tumor, proteogenomics, marks a transformative milestone for preclinical cancer research. In this paper, we initially provided an overview of proteogenomics in cancer research,spanning genomics, transcriptomics, and proteomics. Subsequently, the applications were introduced and examined from different perspectives, including but not limited to genetic alterations, molecular quantifications, single-cell patterns, different post-translational modification levels, subtype signatures,and immune landscape. We also paid attention to the combined multi-omics data analysis and pancancer analysis. This paper highlights the crucial role of proteogenomics in preclinical targeted cancer therapy research, including but not limited to elucidating the mechanisms of tumorigenesis, discovering effective therapeutic targets and promising biomarkers, and developing subtype-specific therapies.
引用
收藏
页码:56 / 76
页数:21
相关论文
共 50 条
  • [31] Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy
    Hajimolaali, Mohammad
    Dorkoosh, Farid Abedin
    Antimisiaris, Sophia G.
    JOURNAL OF LIPOSOME RESEARCH, 2024, 34 (04) : 671 - 696
  • [32] Preclinical targeted alpha therapy for subcutaneous melanoma
    Allen, BJ
    Rizvi, SMA
    Tian, Z
    MELANOMA RESEARCH, 2001, 11 (02) : 175 - 182
  • [33] Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives
    Luo, Dong
    Liu, Yunmei
    Lu, Zhengmao
    Huang, Lei
    MOLECULAR MEDICINE, 2025, 31 (01)
  • [34] Advancements in Polymeric Nanocarriers to Mediate Targeted Therapy against Triple-Negative Breast Cancer
    Fatima, Mahak
    Sheikh, Afsana
    Abourehab, Mohammed A. S.
    Kesharwani, Prashant
    PHARMACEUTICS, 2022, 14 (11)
  • [35] Efficacy of VEGFR2 targeted mAb therapy in preclinical cancer models resistant to antiangiogenic therapy
    Surguladze, D.
    Plym, M. J.
    Malaby, J.
    Prewett, M.
    Rutstein, M.
    Schwartz, J.
    Lu, D.
    Witte, L.
    Tonra, J. R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 75 - 75
  • [36] Advancements in Zebrafish Models for Breast Cancer Research: Unveiling Biomarkers, Targeted Therapies, and Personalized Medicine
    Wawruszak, Anna
    Okon, Estera
    Dudziak, Karolina
    MEDICAL SCIENCE MONITOR, 2023, 29
  • [37] Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage
    Rosenholm, Jessica M.
    Mamaeva, Veronika
    Sahlgren, Cecilia
    Linden, Mika
    NANOMEDICINE, 2012, 7 (01) : 111 - 120
  • [38] Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy
    Espedal, Heidi
    Fonnes, Tina
    Fasmer, Kristine E.
    Krakstad, Camilla
    Haldorsen, Ingfrid S.
    CANCERS, 2019, 11 (12)
  • [39] Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
    Patricia Egusquiaguirre, Susana
    Igartua, Manuela
    Maria Hernandez, Rosa
    Luis Pedraz, Jose
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (02): : 83 - 93
  • [40] Proteogenomics in Cancer: Then and Now
    Wang, Xiu-Yun
    Xu, Yan-Ming
    Lau, Andy
    JOURNAL OF PROTEOME RESEARCH, 2023, 22 (10) : 3103 - 3122